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London, UK, 2017
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Roosmarijn E. Vandenbrouke5,6, Ignacio A. Romero7, Matthew Campbell8, Gert Fricker9, Birger Brodin10, 
Heiko Manninga11, Pieter J. Gaillard12, Markus Schwaninger13, Carl Webster14, Krzysztof B. Wicher15 
and Michel Khrestchatisky16,17
Abstract 
This is a report on the CNS barrier congress held in London, UK, March 22–23rd 2017 and sponsored by Kisaco 
Research Ltd. The two 1‑day sessions were chaired by John Greenwood and Margareta Hammarlund‑Udenaes, 
respectively, and each session ended with a discussion led by the chair. Speakers consisted of invited academic 
researchers studying the brain barriers in relation to neurological diseases and industry researchers studying new 
methods to deliver therapeutics to treat neurological diseases. We include here brief reports from the speakers.
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Background
The blood–brain barrier (BBB), and the other blood–tis-
sue barrier sites of the central nervous system (CNS), 
have been the subject of extensive research since 
their discovery over 100  years ago. Despite consider-
able advances in our understanding of the structural and 
functional interface of the BBB, there remain many gaps 
in our knowledge particularly regarding its role in disease 
and the challenges it presents to therapeutic intervention. 
In recent decades the classic concept of the BBB has also 
evolved such that it now cannot be considered in isola-
tion from other cellular components of the CNS. Accord-
ingly, the emergence of the concept of the neurovascular 
unit (NVU) has re-shaped our approach to studying the 
BBB. In addition, other blood–tissue interfaces, such as 
the blood–cerebrospinal fluid and blood–retinal barriers, 
are also providing additional insight into the communica-
tion between the blood and the CNS.
Our understanding of the normal structure and func-
tion of the blood–CNS barriers is well advanced but their 
roles in many diseases remains incomplete. Whereas 
blood–CNS dysfunction in some conditions is evident, 
such as in tumours, multiple sclerosis and stroke, in other 
diseases such as Alzheimer’s disease, Parkinson’s disease 
and epilepsy the involvement is less obvious. Indeed, 
gross changes, such as loss of structural integrity have 
clear pathological consequences, whereas subtle changes 
to function may be more difficult to ascertain and place 
within the overall pathogenesis of a disease. Whether 
cause or effect, therapeutic targeting of barrier dysfunc-
tion remains an attractive proposition and drives much 
of the translational research currently underway. How-
ever, various questions concerning barrier susceptibility 
to disease remain outstanding. These include the hetero-
geneity of the vasculature within the CNS and as a conse-
quence its differential response. Indeed, it is known that 
Open Access
Fluids and Barriers of the CNS
*Correspondence:  hazelcjones@btinternet.com 
3 Gagle Brook House, Chesterton, Bicester OX26 1UF, UK
Full list of author information is available at the end of the article
Page 2 of 11Greenwood et al. Fluids Barriers CNS  (2017) 14:31 
in the normal BBB there is endothelial cell heterogene-
ity that is not only dependent on its position throughout 
the vascular bed (i.e. artery versus arteriole, versus capil-
lary, versus venule, versus vein) but also within the same 
region of the vasculature. Moreover, the barrier within 
different structures of the CNS also differs and together 
such heterogeneity will undoubtedly impact on the vari-
able response of the barrier to disease. For example, the 
microvascular pathology observed in diabetes is far more 
pronounced in the retina than in the brain, the response 
of white matter vessels and those in grey matter differ in 
multiple sclerosis, and in meningitis it is the meningeal 
vessels that are susceptible.
Aside from the direct relationship between barrier dys-
function and disease pathogenesis there is another long-
standing and major challenge facing those working in the 
field. This relates to the problems posed by a structurally 
intact barrier that restricts the delivery of therapeutics 
to the brain. For almost 50  years this has proved to be 
largely insurmountable and only recently have advances 
been made that provide some optimism.
In this CNS barrier congress experts from various 
disciplines were brought together to collectively dis-
cuss the best ways to overcome these challenges, and 
pave the way for progress in the treatment of neuro-
logical disease. In recent years, our understanding of 
barriers has undergone re-evaluation and during the 
meeting various pressing questions were discussed. 
These included the role that non-endothelial cells in 
the NVU play in blood–brain barrier regulation, how 
much barrier dysfunction really occurs in different 
CNS diseases, why regional differences exist, and how 
do immune cells impact barrier function. Contrary to 
previous dogma, the CNS barriers are now recognised 
as complex, dynamic, interactive structures that con-
tribute to disease on many levels. Recent advances in 
drug delivery technologies to the CNS were also pre-
sented and discussed at length. Pioneering groups have 
been perfecting new methods to ferry drugs across 
the CNS barriers, particularly the blood–brain barrier 
where access via other routes is problematic. Accord-
ingly, the latest developments in liposome, peptide, 
antibody, and nanoparticle technology for therapeutic 
delivery were showcased and how far these technolo-
gies have to go before they can become widely avail-
able was discussed.
This CNS barrier congress allowed for the presenta-
tion of unpublished data, the exploration of new tech-
nologies, and provided a select platform for academic 
and industrial leaders in the field to form collabora-
tions, exchange ideas and identify new strategies for 
development.
The specialised vascular barriers of the CNS 
and their influence on leukocyte migration
John Greenwood
The specialised vascular endothelial cells that line the 
vessels of the brain and retina form an impermeable 
but selective barrier between the blood and the neural 
parenchyma. Under normal physiological conditions 
this critical interface, termed the blood–brain/retinal 
barrier, strictly limits the passage of solutes and cells 
between these two compartments. During disease, how-
ever, the endothelial cells become activated resulting in 
a change of phenotype and an alteration in their regula-
tory function. Thus, in neuroinflammatory diseases such 
as multiple sclerosis and posterior uveitis, the function of 
these vascular barriers changes resulting in an enhanced 
influx of leukocytes. Accordingly, the endothelial cells 
of the CNS are recognised as playing a pro-active role 
in the propagation, maintenance and possibly resolu-
tion of CNS inflammatory lesions. Over the last few 
decades increasing evidence, from our laboratory and 
that of our collaborators, has shown that the endothelial 
cell responds to adherent leukocytes in variety of ways 
resulting in immediate facilitation of diapedesis to the 
longer-term regulation of gene expression. Many of these 
outside-in signaling cascades are generated through the 
engagement of endothelial immunoglobulin superfamily 
adhesion molecules such as ICAM-1, which act as signal 
transducers leading to the activation of the small GTPase 
rho, eNOS, phospholipase C, protein kinase C, src kinase 
and release of intracellular calcium [1]. In addition, we 
have reported more recently that downstream activation 
of MAP kinases, re-arrangements of the actin cytoskel-
eton and tyrosine phosphorylation of various cytoskeletal 
associated proteins results in the activation of divergent 
inflammatory outcomes [2]. Finally, we have established 
that the tightness of the endothelial cell junction and 
cell cytoskeletal stiffness dictates the route of leukocyte 
transmigration [3]. Deciphering the end-points of these 
signaling networks and identifying potential pharmaco-
logical targets, remains a major focus of the laboratory.
Non‑VEGF mediated breakdown of the blood–
retinal barrier: alternative strategies to treat 
diabetic macular oedema
Alan W. Stitt
Diabetic macular oedema (DMO) occurs as a symptom 
of diabetic retinopathy and often leads to significant 
vision-loss [4]. The condition is characterised by pro-
gressive breakdown of the blood retinal barrier (BRB) as 
a result of tissue ischaemia and/or inflammation which 
drive imbalances in vasoactive cytokines and growth fac-
tors causing compromise of normal neuroglial–vascular 
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interactions and endothelial dysfunction [4]. Neutrali-
sation of vascular endothelial growth factor (VEGF) 
using intravitreal injection of humanised antibodies has 
become a mainstream treatment for DMO. Unfortunately 
this is not effective for all DMO patients [5] and there is 
a need for additional therapeutic approaches which could 
be used instead of, or in conjunction with, current anti-
VEGF drugs.
Our groups have recently focused on the permeability-
inducing agent lysophosphatidylcholine (LPC) which is 
produced through activity of the enzyme lipoprotein-
associated phospholipase  A2 (Lp-PLA2). Using a range of 
in vitro and in vivo approaches, we have recently shown 
that inhibition of Lp-PLA2 can prevent diabetes-induced 
compromise of the BRB in a manner that is compara-
ble to intravitreal VEGF neutralisation [6]. Importantly, 
these protective effects were additive when both targets 
were inhibited simultaneously. Our mechanistic stud-
ies also demonstrated that LPC potently induced per-
meability, and that there was a coalescence of the LPC 
and VEGF pathways via a common VEGF-receptor-2 
mediated mechanism [6, 7]. We have concluded that Lp-
PLA2 may be a useful therapeutic target for patients with 
DMO, perhaps in combination with currently adminis-
tered anti-VEGF agents. Such studies demonstrate the 
utility of studying “real-world” clinical scenarios whereby 
new approaches can be evaluated alongside the current 
gold-standard therapies and offer hope for patients who 
are non-responsive to current treatment regimes.
The choroid plexus is an important player in the 
induction of neuroinflammation
Roosmarijn Vandenbrouke
The choroid plexus epithelium which forms the blood–
CSF barrier is a unique single layer of epithelial cells 
situated at the interface between blood and cerebrospi-
nal fluid (CSF). The choroid plexus epithelium has sev-
eral different important functions: it forms a barrier to 
protect the brain from fluctuations in the blood, pro-
duces CSF and is responsible for the active removal of 
toxic molecules from the brain and thereby assures brain 
homeostasis. In recent years, the choroid plexus epithe-
lium has gained increasing attention, especially its role in 
different pathologies. Indeed, subtle changes in the cho-
roid plexus epithelial cells will result in changes in CSF 
composition, exerting wide-ranging effects on the brain 
and subsequently affecting disease progression. There-
fore, understanding blood–CSF barrier functionality 
under physiological and pathophysiological conditions 
might open up new therapeutic strategies to treat inflam-
matory brain diseases.
Our research focusses on the effect of both systemic 
inflammation (sepsis) and neuroinflammation (the 
age-related disease Alzheimer’s disease) on the blood–
CSF barrier. More specifically, we study key molecules 
that play a role in the activation of detrimental processes 
at the blood–CSF barrier upon inflammation, focussing 
on barrier integrity and secretory activity. These studies 
might allow us to identify novel therapeutic strategies to 
prevent neuroinflammation.
To address the effect of sepsis, we used intraperitoneal 
lipopolysaccharide (LPS) injection and the caecal ligation 
and puncture (CLP) mouse model, while Alzheimer’s dis-
ease was studied using the intracerebroventricular (icv) 
injection of soluble amyloid β oligomers (AβO) in mice. 
Our studies showed that both systemic [7] and central 
inflammation [8] induce increased blood–CSF barrier 
leakage. Interestingly, these effects could be attributed to 
matrix metalloproteinase (MMP) activity. Additionally, 
peripheral inflammatory triggers induced an increase in 
extracellular vesicle (EV) release by the choroid plexus 
epithelium into the CSF [9]. Detailed analysis by electron 
microscopy and inhibitor studies using the neutral sphin-
gomyelinase 2 inhibitor GW4869, revealed that especially 
the biogenesis of exosomes is increased upon systemic 
inflammation. Strikingly, these choroid plexus-derived 
EVs are able to enter the brain parenchyma, are taken up 
by astrocytes and microglia and transfer a pro-inflamma-
tory message to the brain [9]. Interestingly, we observed 
that the icv injection of AβO has similar effects on the 
extracellular vesicle production of the choroid plexus epi-
thelial cells.
Clearly, our data show that both peripheral and central 
inflammatory triggers affect barrier and secretory activity 
of the choroid plexus epithelium and these results might 
open up new therapeutic strategies to treat neuroinflam-
matory diseases.
MicroRNAs and blood–brain barrier function 
in multiple sclerosis
Ignacio A. Romero
Blood–brain barrier dysfunction is a major hallmark 
of many CNS disorders such as multiple sclerosis. BBB 
breakdown is characterised by three main features: (1) 
increased permeability across the endothelium; (2) alter-
ation in the expression of cell-surface receptors and/
or transporters; and (3) activation of endothelial cells 
to support leukocyte extravasation into the CNS paren-
chyma. Many of these cerebrovascular pathophysiologi-
cal effects are underpinned by overt acute or chronic 
changes in gene expression in cerebral endothelial cells 
and in other cells of the NVU.
MicroRNAs (miRs) are novel regulators of gene expres-
sion at the post-transcriptional level and may potentially 
play a key role in cerebrovascular pathophysiology. MiRs 
mainly suppress the expression of target genes either by 
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blocking translation or by inducing mRNA degradation. 
We have first identified miRs whose levels in endothelial 
cells change following inflammatory stimuli. Inflamma-
tion induces upregulation of several key inflammatory 
miRs termed inflammiRs (miR-155 and miR-146) in 
brain endothelial cells. By contrast, there are other miRs 
termed brain endothelial housekeeping miRs (miR-125b 
and miR126) whose levels are elevated under quiescent 
conditions but are significantly reduced by pro-inflam-
matory cytokines [10–12]. These inflammation-induced 
changes in the finely-tuned balance of cerebral endothe-
lial miR levels promote cerebrovascular dysfunction. 
For example, miR-155 contributes to BBB leakiness by 
reducing expression of tight junctional and focal adhe-
sion components but it also promotes leukocyte firm 
adhesion to brain endothelium by indirectly increasing 
expression of cell adhesion molecules. Conversely, miR-
146 inhibits leukocyte firm adhesion to brain endothe-
lium by suppressing expression of key activators of the 
NF-κB pathway. Brain endothelial miRs could potentially 
be considered for targeted prophylaxis and therapies for 
BBB dysfunction.
However, we are still far from validating cerebrovas-
cular miRs as potential therapeutic or prophylactic tar-
gets for neurovascular dysfunction in inflammatory and/
or autoimmune disorders. First, there is the likelihood 
that several different miRs have combinatorial effects in 
specific CNS pathologies. Second, individual miRs likely 
have multiple gene targets and effects on other endothe-
lial cellular pathways that contribute to the pathogenesis 
of inflammatory disease. In addition, non-specific deliv-
ery of miR modulators into other tissues or organs (e.g. 
liver, kidney) could cause unwanted side effects unless 
very specific delivery systems targeted at the cerebro-
vascular bed are available, Nevertheless, the potential 
for manipulating this novel class of regulators of gene 
expression for therapeutic purposes is huge and should 
be given considerable attention in the near future.
Dose dependent expression of claudin‑5 is a 
modifying factor in neurological diseases
Matthew Campbell
Abnormalities in neuronal functioning in psychiat-
ric conditions may derive in part from abnormalities in 
blood vessel–neuron interactions [13]. We have shown 
that the claudin-5 gene, a central component of the para-
cellular pathway of the BBB is associated with schizo-
phrenia in individuals with the chromosomal disorder 
22q11 deletion syndrome (22q11DS), a condition that 
confers a 30-fold increased lifetime risk of develop-
ing schizophrenia. A variant in this gene results in up 
to 50% less protein product and a targeted suppression 
of claudin-5 in distinct brain regions, or in an inducible 
“knockdown” mouse, identifies strong phenotypic cor-
relations with schizophrenia. Additionally, post-mortem 
human schizophrenia donor brain tissues show evi-
dence of BBB dysfunction, while some of the most com-
mon anti-psychotic drugs can directly regulate claudin-5 
expression. Identifying the underlying cause of neuropsy-
chiatric conditions at the level of the BBB suggests novel 
drug entities targeting the integrity of the BBB may have 
utility in treating these debilitating and socially isolat-
ing condition [14, 15]. All work involving animals was 
approved by the institutional ethics committee and all 
national licences were in place prior to commencement 
of work.
Impact of ABC transporters on blood–brain barrier 
function
Gert Fricker
The CNS requires a well-balanced homeostasis. There-
fore, it is protected by the BBB, which is set up by 
endothelial cells of brain microvessels. These cells act as 
a dynamic regulator of ion balance, mediator of nutrient 
transport and barrier to harmful molecules. A central role 
accords to ATP-binding-cassette (ABC) export proteins, 
predominantly P-glycoprotein (P-gp, ABCB1), breast 
cancer resistance protein (BCRP, ABCG2) and multi-
drug resistance related proteins (MRPs, ABCCs). ABC 
transporters are predominantly expressed in microvessel 
endothelial cells, but are also located on other cell types, 
such as astrocytes, microglia, and neurons. In microves-
sel endothelial cells ABC transporters exhibit a polar 
distribution. P-gp is primarily found in luminal mem-
branes, however, there is evidence that it also localizes 
to a certain amount to abluminal membranes as well as 
to pericytes and astrocytes. Studies using a fluorescent 
labeled construct of P-gp indicate that the export pump 
is not organized as a single molecule within membranes 
but forms clusters of several proteins close together [16]. 
BCRP appears to be predominantly located at the lumi-
nal surface of endothelial cells. Mrps are also expressed 
at the BBB, however, there is still considerable discus-
sion about the extent of expression, involvement in drug 
transport and subcellular localization. Inhibition of ABC 
transporters significantly alters the brain disposition of 
transporter substrates as illustrated by studies in human: 
positron emission tomography (PET)-imaging revealed 
that cyclosporin A modulation of P-gp increased transfer 
of verapamil into the brain. In another PET-trial uptake 
of loperamide into the CNS was enhanced after inhibi-
tion of efflux pumps by tariquidar.
Various mechanisms control expression and func-
tion of ABC transporters. Regulation occurs either by 
ligand-activated transcription factors or by external 
stress signals which modulate ABC transporter function. 
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The nuclear receptors PXR (pregnane X receptor), AhR 
(arylhydroxycarbon-receptor), CAR (constitutive andro-
stane receptor), VDR (vitamin D receptor) and PPAR-γ 
(peroxisome proliferator-activated receptor) and related 
signaling events are of particular interest, since they bind 
many xenobiotics and subsequently upregulate ABC-
transporter expression. ABC transporters also contrib-
ute to various CNS diseases. For example, brain tissue 
from Alzheimer patients showed an inverse relationship 
between P-gp expression and disease progress and inhi-
bition of P-gp in a rodent Alzheimer model increased 
amyloid-β levels in brain. Studies showed that St. John’s 
Wort administration to mice resulted in significant 
reductions of parenchymal amyloid-β accumulation as 
well as in a moderate increase in cerebrovascular P-gp 
expression [17]. In summary, ABC-transporters are of 
outstanding relevance for the proper function of the 
blood–brain barrier. They are very sensitive to exogenous 
and endogenous stimuli and are involved in the progres-
sion of various CNS diseases.
In vitro models of the blood–brain barrier, pro’s 
and con’s
Birger Brodin
The brain capillary endothelium serves as a gateway 
for exchange of nutrients, hormones and metabolites 
between plasma and brain parenchyma, and acts as a bar-
rier for CNS uptake of the majority of drug compounds. 
Mechanistic in  vivo investigations of drug and nutri-
ent transport, signalling and metabolism in the brain 
endothelium can be difficult to perform, since the brain 
endothelium is embedded within a complex structure, 
the neurovascular unit, itself within the multi-compart-
ment brain and fluid system.
Cell isolation and culture protocols for growing brain 
endothelial cells in monolayers, either in monoculture or 
in co-culture with other cell types of the NVU, have been 
developed over the last 40 years. Although no ideal cell 
culture model of the blood–brain barrier is yet available, 
the in vitro models have evolved to become useful tools 
in the studies of barrier biology and drug delivery.
In vitro models based on primary cell cultures of ani-
mal origin (typically bovine, porcine or murine models) 
display endothelial cell morphology, expression of BBB 
tight junction proteins and high transendothelial electri-
cal resistance, subject to astrocyte induction [18]. They 
display vectorial transport of efflux transporter sub-
strates, indicative of luminal expression of ABC-type 
pumps [19]. The major drawback of these models may be 
downregulation of a number of solute carrier family pro-
teins (SLC’s) as compared to the expression in vivo. Alter-
natively, immortalized cell lines of mouse, rat and human 
origin, in general without astrocyte induction, tend to be 
considerably more leaky than the in  vitro models based 
on primary cell cultures. Some immortalized cell lines 
do, however, show relatively higher expression of some 
BBB-specific SLC transporters than the models based 
on primary cell cultures and may serve as excellent tools 
for studies of uptake, receptor activation and some signal 
transduction systems. A recent approach, generation of 
in vitro models of the BBB using human stem cells, has 
resulted in cell monolayers with both high monolayer 
tightness and expression of BBB-specific marker proteins 
[20]. However, the stem cell cultures are not yet widely 
used, and have not been fully validated with respect to 
transport properties and functional transporter profiling.
In brief, established in vitro blood–brain barrier mod-
els all have their advantages and drawbacks. Primary 
cell lines of bovine, porcine and rodent origin generate 
tight monolayers whereas immortalized cell lines may 
have higher transporter expression levels but less tight-
ness. Models derived from human stem cells shows great 
promise, but are not yet fully characterized.
Measuring blood–brain barrier transport 
of drugs—the hurdle in drug discovery 
and development
Margareta Hammarlund‑Udenaes
Measurement of total drug levels in the brain has been a 
common but unhelpful practice for many years in drug 
discovery programs aiming at central drug effects. The 
paradigm has changed with the introduction of the phar-
macologically more important unbound brain interstitial 
fluid to unbound blood concentration ratio,  Kp,uu,brain, 
and with more high-throughput methods to estimate 
this parameter (the brain slice and the brain homogenate 
techniques).
By combining several of these measurements, the com-
binatory mapping approach (CMA) allows estimation of 
not only BBB transport, but also intracellular distribution 
of the pharmacologically active, unbound drug moiety 
[21]. CMA can also be used to assess possible lysoso-
mal accumulation that may predict phospholipidosis as 
a serious side effect. The technique allows estimation of 
brain regional differences in BBB transport and binding, 
something that can influence effect/side effect patterns 
of drugs. In a study of six antipsychotic drugs, we found 
very different BBB and intracellular distribution pat-
terns of the drugs [22]. There was a sixfold difference in 
regional BBB transport of risperidone (a P-glycoprotein 
substrate), with a more efficient efflux in cerebellum than 
in frontal cortex in rats, while other drugs such as que-
tiapine and clozapine showed very small differences in 
regional transport. In a separate study utilizing the CMA, 
we did not find any change in the BBB transport of five 
selected drugs in disease models of Alzheimer’s disease 
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(ArcSwe) and Parkinson’s disease (A30P) compared with 
wild-type mice, counteracting the view that the BBB is 
leaky in disease.
Microdialysis was used to study if liposomal delivery 
would improve the brain uptake of methotrexate [23]. 
With microdialysis it was possible to separate the lipo-
somally-encapsulated drug from released drug in blood, 
and to measure the released compound in brain. While 
liposomes based on hydrogenated soy phosphatidylcho-
line did not change BBB uptake at all compared with 
administering the free drug, the egg-yolk phosphatidyl-
choline liposomes increased the uptake into the brain 
threefold, reaching concentrations that could be pharma-
cologically active also in humans.
In conclusion, there are three main conceptual parts 
of brain drug transport, the rate of transport, measured 
as the permeability surface area product, the extent of 
transport measured with  Kp,uu,brain, and the nonspecific 
intra-brain binding, all contributing to different aspects 
of brain drug delivery. The extent of transport is consid-
ered clinically most relevant, as it measures the steady 
state relationship across the BBB, quantifying active 
efflux and influx processes.
NEUWAY pharma: qualified for CNS delivery
Heiko Manninga
NEUWAY Pharma GmbH, a German based biotech 
company, is focusing on the preclinical and clinical 
development of innovative therapeutics for treatment of 
brain diseases based on its proprietary CNS Drug Deliv-
ery Platform.
The presented platform is based on a protein derived 
from the JC-Virus, which naturally forms capsules, 
named Engineered Protein Capsules (EPCs). EPCs 
may be used as carrier to transport highly active drug 
substances—ranging from small molecules to large 
nucleic acid strands—across the intact BBB. NEU-
WAY has demonstrated that its EPC-based proprietary 
CNS drug delivery platform can deliver plasmids over 
the blood brain barrier into CNS cells leading to gene 
expression in the brain. In a proof of concept study it 
was shown that intravenous injection of EPCs loaded 
with DNA encoding for luciferase induced an activity 
of the resulting enzyme, which was detected by bio-
luminescent signals in the brain (Fig.  1). More accu-
rate studies of the brains of such treated mice clearly 
showed that the signals from the brain cells are beyond 
the blood–brain barrier and not from other cells, e.g., 
blood vessels.
As EPCs can carry large nucleic acid strands, they 
may be useful for gene therapy of rare diseases. NEU-
WAYs current development focuses on lysosomal stor-
age diseases, like metachromatic leucodystrophy. For 
this and other rare diseases, NEUWAY plans to run its 
own clinical development programs. NEUWAY is also 
open to partner its CNS drug delivery platform with 
Fig. 1 The enzyme luciferase produces light when the conversion of luciferin occurs. If a plasmid coding for luciferase is administered intravenously, 
no light signal can be detected (left mouse). The enzyme was degraded in the bloodstream. If the luciferase plasmid packaged in Engineered Pro‑
tein Capsules (EPCs) is applied directly into the brain (intracerebral, i.c., middle mouse), a luminous signal can be detected there after administration 
of luciferin. This is also observed when the luciferase plasmid is packaged in EPCs and injected intravenously (i.v., right mouse)
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pharmaceutical or biotech companies preferably if large 
indications, like Alzheimer’s disease, are addressed.
Investigations conformed to the Guide for the Care and 
Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 
1996).
All animal procedures were approved by the appropri-
ate state agency (Protocol Number W17/11).
Liposomal technology and the blood–brain barrier
Pieter J. Gaillard
2-BBB is successfully harnessing liposomal technology to 
mediate safe targeting and enhanced drug delivery to the 
brain. The G-Technology® platform has been shown to 
enhance transport of therapeutics across the blood–brain 
barrier. Preclinical studies with the lead product, 2B3-
101, containing doxorubicin, demonstrated significantly 
enhanced delivery and improved survival of mice in com-
parison to currently available compounds.
Phase I clinical trials with 2B3-101 have been com-
pleted, with Phase IIa set to determine preliminary anti-
tumor efficacy at the maximum tolerated dose. The study 
population of this phase I/IIa trial consisted of patients 
who met all of the inclusion criteria and none of the 
exclusion criteria, and provided written informed con-
sent. The protocol, any amendments and all other appli-
cable study documents for the study were reviewed by 
the Independent Ethics Committees (IECs) of the fol-
lowing countries: NL: The “Nederlands Kanker Instituut 
Antoni van Leeuwenhoek Ziekenhuis”; BE: The “Asso-
ciation Hospitaliere de Bruxelles-Centre des Tumeurs de 
l’ULB”; USA: The “Office of Human Research Ethics of 
the University of North Carolina at Chapel Hill”; FR: The 
“Comite De Protection Des Personnes Ile De France III”. 
Clinical trial identifier is NCT01386580.
2-BBB’s second product in development, 2B3-201, con-
taining methylprednisolone, is designed to treat patients 
with acute neuroinflammation. Superior efficacy, reduced 
side effects and enhanced plasma circulation half-life 
have been shown in rodent models, in comparison to 
competitive compounds. A phase I study in healthy vol-
unteers was completed, addressing safety, tolerability 
and pharmacokinetics, and markers for pharmacologi-
cal proof-of-concept. Collectively, preclinical and clinical 
evidence to date has demonstrated that G-Technology® 
offers a promising platform to safely enhance delivery of 
drugs to the brain. The study was approved by the Medi-
cal Ethics Committee of the BEBO Foundation (Assen, 
The Netherlands). Subjects provided written informed 
consent. Clinical trial identifier is NCT02048358.
The blood–brain barrier in gene therapy: hurdle or 
target?
Markus Schwaninger
Gene therapy provides attractive therapeutic options for 
the many diseases for which no treatment is still avail-
able. The adeno-associated virus (AAV) is a safe and 
efficient tool to transfer genes. However, conventional 
AAV-based vectors do not cross the BBB when adminis-
tered systemically. This obstacle can be solved by admin-
istering vectors either intrathecally or using vectors 
based on AAV serotype 9 that cross the BBB to a limited 
extent. Still another approach is to target the BBB itself. 
In order to develop a brain endothelial selective vector, 
a novel strategy for in  vivo screening of random ligand 
libraries displayed on viral capsids was used [24]. Several 
rounds of in vivo selection resulted in AAV-BR1, an AAV 
vector with unprecedented selectivity for brain endothe-
lial cells after systemic intravenous administration. Due 
to its specific features, this vector allows for modulating 
and repairing the BBB. Its efficacy was tested in a mouse 
model of the hereditary disease incontinentia pigmenti 
[25], in which a deficiency of the Nemo gene leads to a 
loss of brain endothelial cells and breakdown of the BBB. 
Consequently, patients suffer from neurological disability 
and epileptic seizures. Intravenous injection of AAV-BR1 
transferring the Nemo gene was able to largely reduce 
endothelial cell death and to ameliorate disruption of 
the BBB. Mice treated with AAV-BR1-Nemo showed 
less activation of astrocytes. Importantly, the occur-
rence of focal epileptic seizures was significantly reduced 
by the gene therapy [26]. Probably due to its high brain 
endothelial selectivity, the vector did not induce hepa-
tocellular carcinoma or other adverse effects that have 
been observed in rodents during gene therapy with AAV 
vectors. Previous studies suggest that transduced brain 
endothelial cells may release enzymes that are missing in 
the CNS [27]. Thus, transducing brain endothelial cells 
with gene vectors offers the opportunity to overcome the 
BBB and to supply diverse proteins to the diseased brain 
(Fig. 2). The conceptual progress of this approach is that 
the BBB is no longer considered as a hurdle but as the 
target of a successful therapy.
Antibody therapeutics for CNS diseases and their 
delivery across the BBB
Carl Webster
The BBB protects and regulates the homeostasis of the 
brain. However, this barrier also limits the access of 
drugs, including large molecule therapeutics, to the brain 
and results in sub-therapeutic concentrations of drug 
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reaching CNS targets. MedImmune have utilised their 
antibody engineering platform to develop a fully human 
monoclonal antibody that targets the blood brain bar-
rier to deliver therapeutics to the CNS. The antibody was 
isolated from a phage display library by competitive elu-
tion using the known BBB transporting antibody FC5. 
A combination of pharmacodynamic (PD) and pharma-
cokinetic (PK) assays were used to confirm central pen-
etration. In mice, the peripheral PK was in line with the 
expected half-life for a human antibody and showed no 
target mediated clearance at doses from 0.45 to 45  mg/
kg. Brain penetration was around 3% of injected dose and 
persisted beyond 7 days. To confirm the antibody present 
in the CNS was able to access central targets, a fusion to 
interleukin-1 receptor antagonist (IL-1RA) was made. 
IL-1 is mediator of neuropathic pain and its antagonism 
is analgesic. Partial ligation of the sciatic nerve results 
in a neuropathic pain phenotype that manifests through 
increased sensitivity to mechanical pressure on the hind 
paw. Peripheral administration of the BBB-IL-1RA fusion 
resulted in dose dependent analgesia, confirming the 
ability of the BBB antibody to penetrate the CNS. How-
ever, the doses required were high and this fusion pro-
tein would not represent a commercially viable treatment 
for neuropathic pain. Other molecular targets represent 
better points of intervention in the pain signalling path-
ways and therefore an antibody against the ATP gated ion 
channel P2X4 was developed. P2X4 regulates the physi-
ology and pathophysiology of spinal microglia and is 
implicated in pain signalling. Channel blocking antibod-
ies against mouse P2X4 were obtained by immunising 
rats with recombinant mouse P2X4. Approximately 5000 
hybridoma lines binding to P2X4 were identified of which 
28 showed blocking activity. Lead antibodies were tested 
by intrathecal administration to mice where analgesia in 
the neuropathic pain model was demonstrated. Periph-
eral administration resulted in analgesia only when fused 
to the BBB antibody, confirming central exposure of the 
drug molecule was required. Doses as low as 3  mg/kg 
produce statistically significant analgesia, and this offers 
hope of a treatment to many people suffering from neu-
ropathic pain.
All procedures described here were performed in 
accordance with the Animals (Scientific Procedures) Act 
1986 and were approved by the MedImmune local ethics 
committee.
Harnessing bispecific antibodies to overcome the 
blood–brain barrier
Krzysztof B. Wicher
Penetration of the BBB remains a significant impediment 
in development of biologics for CNS-related diseases. 
To identify efficient brain-shuttles, we used shark single 
domain antibody phage libraries in a combined in  vitro 
and in  vivo selection process. To achieve the highest 
discovery rate of brain-penetrant clones, we employed 
next generation sequencing of phagemid DNA after sub-
sequent rounds of selection. This way, we identified a 
panel of TfR1-specific shark antibodies, which are effi-
ciently transported to mouse brain parenchyma. One of 
these antibodies (B2) fused to human IgG1 Fc showed 
more than 12-fold better brain uptake than the control, 
reaching therapeutic concentrations (5  nM) upon sin-
gle intravenous injection of 25  nmol/kg (~  1.9  mg/kg). 
Most of the brain-associated B2-hFc was found in brain 
parenchyma. Immunohistochemistry analyses showed 
the protein present both in the intestinal fluid and in the 
cells, including neurons. B2 antibody is safe upon admin-
istration of high doses in mice, as manifested by lack of 
significant acute adverse reactions or changes in blood 
Fig. 2 After intravenous administration of the vector AAV‑BR1‑eGFP (enhanced Green Fluorescent Protein) to mice most brain endothelial cells 
expressed eGFP. eGFP expression in other tissues was low. In exchange of eGFP other genes can be selectively expressed in brain endothelial cells. 
The figure shows a representative section of the thalamus stained for the endothelial cell marker CD31 and eGFP
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morphology of injected animals. It binds to human TfR1 
with comparable affinity as to mouse TfR1, but does not 
bind to TfR2. Moreover, in silico analysis indicates that 
B2 antibody would have relatively low immunogenic 
properties in humans.
We next constructed several different variants of bi-
specific antibodies composed of B2 and rituximab, a 
well characterized anti human CD20 specific antibody 
used to treat peripheral B cell lymphomas. Many of these 
variants shuttle efficiently to brain and provide up to 14× 
better exposure than original antibody. The hybrid pro-
teins retain their binding to both TfR1 and CD20 and at 
least some of them appear to mediate antibody-depend-
ent cell cytotoxicity response on human  CD20+ve, but not 
on  CD20−ve, cells, similar to that of rituximab. Thus, they 
offer possible therapeutics for multiple sclerosis and cer-
ebral B-cell lymphoma.
All research procedures/experiments described here 
were performed in accordance with Animals Scientific 
Procedures Act 1986 and European Directive 2010/63/
EU. All studies performed were approved by the Royal 
Veterinary College Animal Welfare and Ethics Review 
Body and comply with the UK Home Office guidelines 
and codes of conduct.
Drug delivery across the blood–brain barrier using 
peptide conjugates
Michel Khrestchatisky
Drug delivery to the brain is hindered by the BBB. Recep-
tor-mediated transport/transcytosis (RMT) can be used 
to shuttle therapeutics into the brain in a non-invasive 
manner. We developed peptide- and nanobody-based 
ligands that target specific receptors and that can be 
used as vector molecules to transport drugs or imaging 
agents across the BBB. Members of the low density lipo-
protein receptor (LDLR) family appear relevant to deliver 
drugs into cells and organs and we report results on the 
development of peptide-vectors that target the rodent 
and human LDLR. Initial screening of complex peptide 
libraries followed by chemical optimization led to the 
development of a family of short cyclic peptides (eight 
natural or non-natural residues) with distinct properties 
in terms of affinity, stability and biodistribution.
Real time two-photon microscopy experiments on mice 
demonstrated the ability of a lead peptide-vector to trans-
port a non-permeable agent such as RhoRedX across 
the BBB and the blood–spinal cord barrier. As a further 
proof of concept, following intravenous (iv) administra-
tion in mice, peptide-vectors efficiently transported to 
the brain molecules such as opiate peptides or neuro-
peptides, all known to poorly cross the BBB. In particu-
lar, a vector-neurotensin conjugate is under preclinical 
development for its potential to induce pharmacological 
hypothermia with neuroprotective effects in acute exci-
totoxic neurodegeneration.
Some tumors including glioblastoma are associated 
with high-level expression of receptors involved in cell 
metabolism such as the LDLR. Conjugating our peptide-
vectors to 68Gallium-NODAGA or -DOTA allowed PET 
imaging of glioblastoma in mouse brain. Others have 
shown that nanoparticles or liposomes functionalized 
with one of our lead peptide-vectors (peptide-22) perme-
ate the BBB and exhibit higher glioma distribution than 
non-functionalized nanoparticles or liposomes; function-
alized nanoparticles or liposomes loaded with paclitaxel 
and doxorubicin respectively elicit significantly pro-
longed life span of glioma-bearing mice [27, 28].
The lead peptide vectors also allowed uptake of vector-
ized protein cargos such as an antibody Fc fragment by 
brain endothelial cells and transport across an in  vitro 
BBB model, and in vivo into the brain following iv admin-
istration in mice [29]. The peptide-vectors are currently 
assessed with industrial partners for their potential to 
transport therapeutic antibodies into the brain. In sum-
mary, we have developed a family of chemically opti-
mized peptide-vectors that can be conjugated to a variety 
of different compounds such as small organic molecules, 
peptides, siRNAs and proteins including therapeutic 
antibodies. These peptide vectors bind the rodent and 
human LDLR and promote transport of cargos across the 
BBB and brain uptake in rodents. Such peptide-vectors 
appear promising for CNS delivery of different classes of 
drugs.
Conclusions
From the variety of talks, it was clear that significant pro-
gress is being made in understanding control processes 
at brain barrier interfaces and in novel drug delivery 
methods. Modification of the normal barrier processes 
occurs in inflammatory situations through signalling 
cascades which can be manipulated, barrier gene expres-
sion can be modified with micro RNAs and control can 
be exerted over barrier transporter functions. Techniques 
for enhancing delivery of therapeutics to the CNS involve 
cleverly-devised delivery vehicles such as drug-carrying 
liposomes, endothelial-specific viral vectors, peptide 
conjugates, engineered protein capsules, nanoparticles, 
bi-specific antibodies and human monoclonal antibodies. 
Methods to test the efficacy of therapeutic delivery were 
discussed using both in  vitro and in  vivo techniques. 
Overall this was a stimulating conference bringing 
together scientists from a number of different disciplines.
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